Decrease (-) Restore Default Increase (+)

Clinical Trials

Topic   ANCA Associated Vasculitis
Title   A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophospha
Summary   You may qualify for a Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Study
Description   The purpose of this clinical trial is to determine whether an investigational treatment, when added to either rituximab or cyclophosphamide, can improve your vasculitis disease activity, kidney function, and/or quality of life.
IRB Number   NA
Inclusion/Notes   You may qualify for this Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Study, if:
  • Clinical diagnosis of granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis
  • Aged at least 18 years, with newly-diagnosed or relapsed AAV where treatment with cyclophosphamide or rituximab is needed
Status   Open and On-going
Start Date   07/01/2017
Principal Name   Elise Belilos, MD
Contact Name   Anita Farhi, RN
Email   afarhi@nyuwinthrop.org
Fax   516-663-9587
Current Trial Type   Interventional
Phone   516-663-9582